| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012834751 |
| P356 | DOI | 10.1038/SJ.CLPT.6100461 |
| P698 | PubMed publication ID | 18091759 |
| P5875 | ResearchGate publication ID | 5756790 |
| P2093 | author name string | Robinson WT | |
| P2860 | cites work | Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs | Q48665583 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 358-360 | |
| P577 | publication date | 2007-12-19 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Innovative early development regulatory approaches: expIND, expCTA, microdosing | |
| P478 | volume | 83 |
| Q51538339 | Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare |
| Q80509414 | Back to the future: driving innovation in drug development |
| Q58158341 | Biomedical Conventions and Regulatory Objectivity |
| Q56430923 | Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics |
| Q51521654 | Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms |
| Q37804958 | Comparative requirements for exploratory clinical trials — eIND, eCTA and microdosing |
| Q36732115 | Designing phase 0 cancer clinical trials |
| Q30491850 | Evaluation of agile designs in first-in-human (FIH) trials--a simulation study |
| Q36016529 | HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension |
| Q37964571 | Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials |
| Q36732058 | Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient |
| Q39907123 | PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications |
| Q93068407 | Phase 0 Clinical Trial Strategies for the Neurosurgical Oncologist |
| Q37358487 | Phase 0 clinical studies in oncology |
| Q34941964 | Phase 0 clinical trials in oncology new drug development |
| Q37184280 | Phase 0 clinical trials: conceptions and misconceptions |
| Q33985780 | Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies |
| Q39934032 | Role of Phase 0 trials in drug development |
| Q37379764 | Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies |
| Q33712782 | The European and American use of exploratory approaches for first-in-human studies |
Search more.